20 hours Ago
Sun Pharma share price today reached ₹1,651.80, a 2.50% rise from its last close of ₹1,611.
50. The rise is despite the overall market downtrend, highlighting Sun Pharma's strength in the pharma industry. The stock has been watched keenly by investors, who have seen it fluctuate over the last few months but remain keen to bet on it in the long term.
Sun Pharma shares have experienced a mixed run, with a fall of 7.97% in the previous month and 10.78% in three months.
However, its long-term growth is still strong, with a five-year compound annual growth rate (CAGR) of 57.38% and a 96.57% return in the last three years.
The Sun Pharma share price as of 11.42 am on March 11, 2025 is Rs. 1,651.
85: The Sun Pharma shares today have a trading volume of 1,663,541, with a total value of transactions being ₹27,488 lakhs. The Volume Weighted Average Price (VWAP) is at ₹1,643, indicating high trading volumes during the session. Sun Pharma has a market capitalization of ₹396,466 crores, making it one of India's top pharmaceutical companies.
With a beta of 0.59, the stock is less volatile than the overall market, and thus a relatively stable investment option. The stock has ranged from a 52-week high of ₹1,960.
35 to a low of ₹1,377.20 over the last year, indicating occasional volatility. The firm has presented good finances, with trailing twelve months (TTM) EPS of ₹47.
69, which represents a 28.48% year-on-year increase. The PE ratio of the stock is 34.
65, below the sector average of 43.91, suggesting undervaluation. Analysts have a target price band of ₹1,895 to ₹2,450, with an average target of ₹2,076.
97, indicating a potential 32.59% rise from current prices. The majority of analysts suggest a ‘Buy’ rating for the stock based on its high earnings growth and expansion plans.
While Sun Pharma stock has a stable financial base, its challenge comes in its specialty portfolio as well as potential impact from the shifting of global tariffs . Although its recent acquisition of Checkpoint Therapeutics for US$355 million (₹3,000 crore) should help add to its specialty drug offerings. Checkpoint Therapeutics is a commercial-stage organization dedicated to the treatments of cancer, including UNLOXCYT, a treatment for late-stage skin cancer that has received approval from the FDA.
Sun Pharma's strategy of broadening its oncology and immunotherapy drugs aligns with this move. Sun Pharma Chairman and Managing Director Dilip Shanghvi said the acquisition would enable the company to capitalize on its international reach and offer new cancer treatment options to patients. Checkpoint CEO James Oliviero added that the transaction would enable quicker global availability of UNLOXCYT.
The deal, subject to regulatory and shareholder approvals, is expected to close in Q2 2025. Sun Pharma's share price today indicates a strong turnaround, with optimistic market sentiment fuelled by its financials and strategic deals. With positive growth prospects projected by analysts, the stock remains one of the top long-term picks for investors.
While the company diversifies its oncology portfolio and overcomes challenges in global markets, it continues to solidify its position as a top player in India's pharma sector..
